Announced
Gilead Sciences to invest $35m in HOOKIPA Pharma.
Synopsis
Gilead Sciences, an American biopharmaceutical company, to invest $35m in HOOKIPA Pharma, a clinical-stage biopharmaceutical company. "Gilead is helping to advance our novel arenaviral platform technology, which has the potential to complement Gilead’s overall research strategies for cures of HIV and HBV," Joern Aldag, HOOKIPA CEO.
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
No credit card required
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.